Evidence map›Paper›PMID 36497938›Full record

ArticleInternational journal of environmental research and public health2022

Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients.

Mateusz Moskal, Piotr Krawiec, Wojciech Zaręba, Izabella Świerczek, Jakub Ratusznik, Wiktor Raputa, Maciej Zieliński, Krzysztof Batko, Mikita Huk, Bogdan Batko

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Mateusz MoskalDepartment of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, 30-705 Cracow, Poland.
Piotr KrawiecDepartment of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, 30-705 Cracow, Poland.
Wojciech ZarębaDepartment of Cardiology, J. Dietl Specialist Hospital, 31-121 Cracow, Poland.
Izabella ŚwierczekDepartment of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, 30-705 Cracow, Poland.
Jakub RatusznikDepartment of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, 30-705 Cracow, Poland.
Wiktor RaputaDepartment of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, 30-705 Cracow, Poland.
Maciej ZielińskiDepartment of Research and Design, Medicine Economy Law Society (MELS) Foundation, 30-040 Cracow, Poland.
Krzysztof BatkoDepartment of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, 30-705 Cracow, Poland.
Mikita HukDepartment of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, 30-705 Cracow, Poland.
Bogdan BatkoDepartment of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, 30-705 Cracow, Poland.ORCID 0000-0003-3999-8093
Andrzej Frycz Modrzewski Krakow University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Real-life data that support effectiveness of secukinumab (SEC), an interleukin 17A inhibitor, in Poland are few. We aimed to evaluate SEC effectiveness based on drug retention and safety measures reported in electronic medical records (EMRs) of patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from two tertiary-care centers in the region of Lesser Poland. A total one-hundred eighty seven (127 PsA and 60 AS) first (

Indexed as

Arthritis, PsoriaticSpondylitis, AnkylosingAntibodies, MonoclonalFemaleHumansMalePolandTreatment OutcomeAntibodies, Monoclonalankylosing spondylitisCentral-Eastern Europeandrug retentioneffectivenesselectronic medical recordspsoriatic arthritisreal-worldsafetysecukinumab

Identifiers

PMID36497938
PMCPMC9737777
OpenAlexW4310183191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.